01:21:02 EDT Tue 23 Oct 2018
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Oncolytics Biotech Inc (2)
Symbol C : ONC
Shares Issued 16,895,732
Close 2018-10-10 C$ 4.43
Recent Sedar Documents

Oncolytics publishes pelareorep abstract

2018-10-11 08:33 ET - News Release

Mr. Michael Moore reports

ONCOLYTICS BIOTECH ANNOUNCES PUBLICATION OF POSITIVE CLINICAL RESULTS FOR PELAREOREP IN ABSTRACT FOR ESMO 2018 CONGRESS

Oncolytics Biotech Inc. has published an abstract on pelareorep (formerly known as Reolysin) for the European Society for Medical Oncology (ESMO) 2018 Congress, taking place Oct. 19 to Oct. 23 in Munich.

The abstract, authored by Sanjay Goel, department of medical oncology, Montefiore Medical Centre, Albert Einstein College of Medicine, Bronx, N.Y., et al., "Dose finding and safety study of Reovirus (Reo) with irinotecan/fluorouracil/leucovorin/bevacizumab (FOLFIRI/B) in patients with KRAS mutant metastatic colorectal cancer (mCRC): Final results," outlines positive clinical trial results for pelareorep in the treatment of patients with KRAS mutant metastatic colorectal cancer. Thirty-six patients received treatment with FOLFIRI/B and pelareorep and the results demonstrated that the combination is not only safe and well tolerated, but that progression-free survival (PFS) and overall survival (OS) are significantly superior to historical data.

The patients receiving the recommended phase 2 dose had a 50-per-cent response rate (three of six patients) and the median PFS and OS were 65.6 weeks and greater than 98.3 weeks (as of May 9, 2018), respectively.

"The noted improvement in both PFS and OS compared to historical results are meaningful for Oncolytics and for the patients," said Dr. Matt Coffey, president and chief executive officer of Oncolytics Biotech. "The favourable results reported from this clinical trial demonstrate the potential of pelareorep to be a compelling treatment choice for a patient population that otherwise has limited therapeutic options after they have progressed on current standard-of-care chemotherapy."

The complete abstract can be found on-line at the ESMO website. Full details from the poster presentation will be announced after it is presented.

Presentation No.:  565P

Date:  Oct. 21, 2018

Lecture time:  1:05 p.m. CEST

Location:  Hall A3 -- poster area networking hub, ICM Munchen, Munich, Germany

Speakers:  Mr. Goel

Session name:  basic science, endocrine tumours, gastrointestinal tumours -- colorectal and non-colorectal, head and neck cancer (excluding thyroid), melanoma and other skin tumours, neuroendocrine tumours, thyroid cancer, and tumour biology and pathology

About pelareorep

Pelareorep is a non-pathogenic, proprietary isolate of the unmodified reovirus: a first-in-class intravenously delivered immuno-oncolytic virus for the treatment of solid tumours and hematological malignancies. The compound induces selective tumour lysis and promotes an inflamed tumour phenotype through innate and adaptive immune responses to treat a variety of cancers.

About Oncolytics Biotech Inc.

Oncolytics is a biotechnology company developing pelareorep, an intravenously delivered immuno-oncolytic virus. The compound induces selective tumour lysis and promotes an inflamed tumour phenotype -- turning "cold" tumours "hot" -- through innate and adaptive immune responses to treat a variety of cancers. Oncolytics's clinical development program emphasizes three pillars: chemotherapy combinations to trigger selective tumour lysis and immuno-therapy and immune modulator (IMiD) combinations to produce innate and adaptive immune responses. Oncolytics is currently conducting and planning additional studies in combination with checkpoint inhibitors and targeted and IMiD therapies in solid and hematological malignancies, as it prepares for a phase 3 registration study in metastatic breast cancer.

We seek Safe Harbor.

© 2018 Canjex Publishing Ltd. All rights reserved.